Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18841329 | 0.77 | P2RX7 (0.37) | P2RX7ALDH1A1NOTUM | |
| SCHEMBL18650799 | 0.71 | USP19 (0.33) | — | |
| SCHEMBL24811362 | 0.70 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL18650825 | 0.66 | OPRM1 (0.33) | — | |
| SCHEMBL24553050 | 0.64 | — | — | |
| SCHEMBL22039725 | 0.64 | — | — | |
| SCHEMBL16190004 | 0.64 | P2RX7 (0.37) | P2RX7 | |
| SCHEMBL13934307 | 0.63 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL1828050 | 0.61 | MAPT (0.36) | P2RX7 | |
| SCHEMBL13684311 | 0.61 | CXCR3 (0.34) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11840529-B2 | Substituted pyrimidines as LRKK2 inhibitors | DENALI THERAPEUTICS INC. (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2017156493-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840529-B2 | Substituted pyrimidines as LRKK2 inhibitors | LRRK2, DTYMK, LMTK2 | P2RX7 1431/4885ALDH1A1 4020/4885NOTUM 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.